[1. SEO K, KITAZAWA T, YOSHINO Y, et al. Characteristics of serum endocan levels in infection. PLoS One. 2015; 10(4):e0123358.10.1371/journal.pone.0123358440433525894539]Search in Google Scholar
[2. COX LA, VAN EIJK LT, RAMAKERS BP, et al. Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock. 2015; 43(4):322-326.10.1097/SHK.000000000000032025565643]Search in Google Scholar
[3. SCHERPEREEL A, DEPONTIEU F, GRIGORIU B, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med.2006; 34(2):532-537.10.1097/01.CCM.0000198525.82124.74]Search in Google Scholar
[4. PALUD A, PARMENTIER-DECRUCQ E, PASTRE J, et al. Evaluation of endothelial biomarkers as predictors of organ failures in septic shock patients. Cytokine. 2015; 73(2):213-218.10.1016/j.cyto.2015.02.01325794660]Search in Google Scholar
[5. YANG J, YANG Q, YU S, et al. Endocan: A new marker for cancer and a target for cancer therapy. Biomed Rep. 2015; 3(3):279-283.10.3892/br.2015.438446722526137222]Search in Google Scholar
[6. BALTA S, MIKHAILIDIS DP, DEMIRKOL S, et al. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis.2015; 243(1):339-343.10.1016/j.atherosclerosis.2015.09.03026448266]Search in Google Scholar
[7. HUANG GW, TAO YM, DING X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci. 2009; 54(2):389-394.10.1007/s10620-008-0346-318592377]Search in Google Scholar
[8. NAULT JC, GUYOT E, LAGUILLIER C, et al. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev.2013; 22(8):1343-1352.10.1158/1055-9965.EPI-13-017923780836]Search in Google Scholar
[9. OZAKI K, TOSHIKUNI N, GEORGE J, et al. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer. 2014; 5(3):221-230.10.7150/jca.7691396307924665346]Search in Google Scholar
[10. TOK D, EKIZ F, BASAR O, et al. Serum endocan levels in patients with chronic liver disease. Int J Clin Exp Med. 2014; 7(7):1802-1807.]Search in Google Scholar
[11. TOSHIKUNI N, OZAKI K, GEORGE J, et al. Serum endocan as a survival predictor for patients with liver cirrhosis. Can J Gastroenterol Hepatol. 2015; 29(8):427-430.10.1155/2015/153805469960926669300]Search in Google Scholar
[12. MØLLER S, HENRIKSEN J.H. Cardiovascular complications of cirrhosis. Gut. 2008; 57:268–278.10.1136/gut.2006.112177]Search in Google Scholar
[13. GOLDBERG, DS, FALLON MB. The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease. Clin Gastroenterol Hepatol. 2015; 13(12):2118-2127.10.1016/j.cgh.2015.04.024]Search in Google Scholar
[14. LOPEZ-TALAVERA JC, CADELINA G, OLCHOWSKI J, et al. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 2016; 23:1616–1621.10.1002/hep.510230644]Search in Google Scholar
[15. KUDDUS RH, NALESNIK MA, SUBBOTIN VM, et al. Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes--an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. J Hepatol. 2000; 33(5):725-732.10.1016/S0168-8278(00)80302-5]Search in Google Scholar
[16. BALDASSARRE M, GIANNONE FA, NAPOLI L, et al. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. Liver Int. 2013; 33:1298–1308.10.1111/liv.1226323890208]Search in Google Scholar
[17. BUSK TM, BENDTSEN F, NIELSEN HJ, et al. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scand J Gastroenterol.2014; 49(9):1103-1110.10.3109/00365521.2014.93491025048331]Search in Google Scholar
[18. MORTENSEN C, JENSEN JS, HOBOLTH L, et al. Association of markers of bacterial translocation with immune activation in decompensated cirrhosis. Eur J Gastroenterol Hepatol.2016; 26(12):1360-6.10.1097/MEG.000000000000021725357217]Search in Google Scholar
[19. WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014; 60(1):197-209.10.1016/j.jhep.2013.07.04423993913]Search in Google Scholar
[20. GASKARI SA, LIU H, D’MELLO C, et al. Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids. J Hepatol.2015; 62(6):1272-7.10.1016/j.jhep.2015.01.021504525925640062]Search in Google Scholar
[21. VOIOSU AM, DAHA IC, VOIOSU TA, et al. Prevalence and impact on survival of hepatopulmonary syndrome and cirrhotic cardiomyopathy in a cohort of cirrhotic patients. Liver Int. 2015; 35(12):2547-2555.10.1111/liv.1286625974637]Search in Google Scholar
[22. NAGUEH SF, APPLETON CP, GILLEBERT TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009; 22:107–133.10.1016/j.echo.2008.11.02319187853]Search in Google Scholar
[23. VOIOSU T, BALANESCU P, BENGUS A, et al. Serum endocan levels are increased in patients with inflammatory bowel disease. Clin Lab.2014; 60(3):505-510.10.7754/Clin.Lab.2013.13033324697130]Search in Google Scholar
[24. BĂLĂNESCU P, LADARU A, BĂLĂNESCU E, et al. Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study. J Clin Lab Anal. 2016; 30(5):368-373.10.1002/jcla.21864680701926331941]Search in Google Scholar
[25. DALLIO M, MASARONE M, CAPRIO GG, et al. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study. J Gastrointestin Liver Dis. 2017; 26(3):261-268.10.15403/jgld.2014.1121.263.dal28922438]Search in Google Scholar
[26. WIESE S, MORTENSEN C, GØTZE JP, et al Cardiac and proinflammatory markers predict prognosis in cirrhosis. Liver Int. 2014; 34(6):e19-30.10.1111/liv.1242824313898]Search in Google Scholar
[27. KARAGIANNAKIS DS, VLACHOGIANNAKOS J, ANASTASIADIS G, et al. Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. Dig Dis Sci. 2013; 58(10):3029-3036.10.1007/s10620-013-2693-y23907333]Search in Google Scholar
[28. LEE W, KU SK, KIM SW, et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014; 229(5):620-630.10.1002/jcp.2448524446198]Search in Google Scholar
[29. BALTA S, MIKHAILIDIS DP, DEMIRKOL S, et al. Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014; 65(9):773-777.10.1177/000331971351349224402320]Search in Google Scholar
[30. TSCHÖPE C, PAULUS WJ. Doppler echocardiography yields dubious estimates of left ventricular diastolic pressures. Circulation. 2009; 120: 810-820.10.1161/CIRCULATIONAHA.109.86962819720947]Search in Google Scholar